nach oben

Erschienen in:

01.09.2014 | Original article

Hypofractionated stereotactic radiotherapy of acoustic neuroma

Volume changes and hearing results after 89-month median follow-up

verfasst von: Manfred Kranzinger, MD, Franz Zehentmayr, Gerd Fastner, Gerhard Oberascher, Florian Merz, Olaf Nairz, Hassan Rahim, Felix Sedlmayer

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this work was to evaluate toxicity and local control following hypofractionated stereotactic radiation treatment with special focus on changes in tumor volume and hearing capacity.

Patients and methods

In all, 29 patients with unilateral acoustic neuroma were treated between 2001 and 2007 within a prospective radiation protocol (7 × 4 Gy ICRU dose). Median tumor volume was 0.9 ml. Follow-up started at 6 months and was repeated annually with MRI volumetry and audiometry. Hearing preservation was defined as preservation of Class A/B hearing according to the guidelines of the American Academy of Otolaryngology (1995).

Results

No patient had any intervention after a median imaging follow-up of 89.5 months, one patient showed radiological progression. Transient increase of tumor volume developed in 17/29 patients, whereas 22/29 patients (75.9 %) presented with a volume reduction at last follow-up. A total of 21 patients were eligible for hearing evaluation. Mean pure tone average (PTA) deteriorated from 39.3 to 65.9 dB and mean speech discrimination score (SDS) dropped from 74.3 to 38.1 %. The 5-year actuarial Class A/B hearing preservation rate was 50.0 ± 14.4 %.

Conclusion

Radiation increases only minimally, if at all, the hearing deterioration which emerges by observation alone. Presbyacusis is not responsible for this deterioration. Transient tumor enlargement is common. Today radiation of small- and medium-sized acoustic neuroma can be performed with different highly conformal techniques as fractionated treatment or single low-dose radiosurgery with equal results regarding tumor control, hearing preservation, and side effects. Hypofractionation is more comfortable for the patient than conventional regimens and represents a serious alternative to frameless radiosurgery.

Anderson BM, Khuntia D, Toma WA et al (2007) Single institution experience treating 100 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 69(Suppl):121

Aoyama H, Onodera S, Takeichi N et al (2013) Symptomatic outcomes in relation to tumor expansion after fractionated stereotactic radiation therapy for vestibular schwannomas: single-institutional long-term experience. Int J Radiat Oncol Biol Phys 85:329–334PubMedCrossRef

Arthurs BJ, Fairbanks RK, Demakas JJ et al (2011) A review of treatment modalities for vestibular schwannoma. Neurosurg Rev 34:265–279PubMedCrossRef

Badakhshi H, Müllner S, Boehmer D et al (2011) Linac basierte stereotaktische Radiochirurgie und stereotaktische fraktionierte Radiotherapie in der Behandlung von vestibulären Schwannomen. Strahlenther Onkol 187 Sondernr 1:75

Bassim MK, Berliner KI, Fisher LM et al (2010) Radiation therapy for the treatment of vestibular schwannoma: a critical evaluation of the state of the literature. Otol Neurotol 31:567–573PubMed

Breivik CN, Nilsen RM, Myrseth E et al (2013) Conservative management or gamma knife radiosurgery for vestibular schwannoma: tumor growth, symptoms, and quality of life. Neurosurgery 73:48–57PubMedCrossRef

Chang SD, Gibbs IC, Sakamoto GT et al (2005) Staged stereotactic irradiation for acoustic neuroma. Neurosurgery 56:1254–1263PubMedCrossRef

Chopra R, Kondziolka D, Niranjan A et al (2007) Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. Int J Radiat Oncol Biol Phys 68:845–851PubMedCrossRef

Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma) (1995) Otolaryngol Head Neck Surg 113:179–180

10.

Dilwali S, Lysaght A, Roberts D et al (2013) Sporadic vestibular schwannomas associated with good hearing secrete higher levels of fibroblast growth factor 2 than those associated with poor hearing irrespective of tumor size. Otol Neurotol 34:748–754PubMedCentralPubMedCrossRef

11.

Dziuba SJ, Curran WJ, Suarez O et al (2000) Single institution experience with 110 patient treated for acoustic schwannomas. Analysis of Gamma Knife stereotactic radiosurgery and Linac fractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 48(Suppl):254

12.

Fuss M, Debus J, Lohr F et al (2000) Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys 48:1381–1387PubMedCrossRef

13.

Goddard JC, Schwartz MS, Friedman RA (2010) Fundal fluid as a predictor of hearing preservation in the middle cranial fossa approach for vestibular schwannoma. Otol Neurotol 31:1128–1134PubMedCrossRef

14.

Hajioff D, Raut VV, Walsh RM et al (2008) Conservative management of vestibular schwannomas: third review of a 10-year prospective study. Clin Otolaryngol 33:255–259PubMedCrossRef

15.

Hansasuta A, Choi CY, Gibbs IC et al (2011) Multisession stereotactic radiosurgery for vestibular schwannomas: single-institution experience with 383 cases. Neurosurgery 69:1200–1209PubMedCrossRef

16.

Hasegawa T, Kida Y, Kato T et al (2011) Factors associated with hearing preservation after Gamma Knife surgery for vestibular schwannomas in patients who retain serviceable hearing. J Neurosurg 115:1178–1186CrossRef

17.

Henzel M, Hamm K, Sitter H et al (2009) Comparison of stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neurinomas according to 3-D tumor volume shrinkage and quality of life. Strahlenther Onkol 185:567–573PubMedCrossRef

18.

House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol Head Neck Surg 93:146–147PubMed

19.

Ishihara H, Saito K, Nishizaki T et al (2004) CyberKnife radiosurgery for vestibular schwannoma. Minim Invasive Neurosurg 47:290–293PubMedCrossRef

20.

Johnson A, Ali AN, Dhabbaan A et al (2012) Short course radiation therapy for acoustic neuromas. Int J Radiat Oncol Biol Phys 84(Suppl):276

21.

Ju DT, Lin JW, Lin MS et al (2008) Hypofractionated cyberKnife stereotactic radiosurgery for acoustic neuromas with and without association to neurofibromatosis Type 2. Acta Neurochir Suppl 101:169–173

22.

Kalapurakal JA, Silverman CL, Akhtar N et al (1999) Improved trigeminal and facial nerve tolerance following fractionated stereotactic radiotherapy for large acoustic neuromas. Br J Radiol 72:1202–1207PubMedCrossRef

23.

Kaplan E, Meier P (1958) Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457–481CrossRef

24.

Kapoor S, Batra S, Carson K et al (2011) Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience. Int J Radiat Oncol Biol Phys 81:647–653PubMedCentralPubMedCrossRef

25.

Karam SD, Tai A, Strohl A et al (2013) Frameless fractionated stereotactic radiosurgery for vestibular schwannomas: a single-institution experience. Front Oncol 3:121PubMedCentralPubMedCrossRef

26.

Kopp C, Fauser C, Müller A et al (2011) Stereotactic fractionated radiotherapy and linac radiosurgery in the treatment of vestibular schwannoma—report about both stereotactic methods from a single institution. Int J Radiat Oncol Biol Phys 80:1485–1491

27.

Lederman G, Lowry J, Wertheim S et al (1997) Acoustic neuroma: potential benefits of fractionated stereotactic radiosurgery. Stereotact Funct Neurosurg 69:175–182PubMedCrossRef

28.

Lin VY, Stewart C, Grebenyuk J et al (2005) Unilateral acoustic neuromas: long-term hearing results in patients managed with fractionated stereotactic radiotherapy, hearing preservation surgery, and expectantly. Laryngoscope 115:292–296PubMedCrossRef

29.

Litre F, Rousseaux P, Jovenin N et al (2013) Fractionated stereotactic radiotherapy for acoustic neuromas: a prospective monocenter study of about 158 cases. Radiother Oncol 106:169–174PubMedCrossRef

30.

Mahadevan A, Floyd S, Wong E et al (2011) Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors. Comput Aided Surg 16:112–120PubMedCrossRef

31.

Makara D, Lederman G, Raden M et al (2003) Fractionated stereotactic radiosurgery (FSR) for acoustic neuroma (AN)—lack of side effects. Int J Radiat Oncol Biol Phys 57(Suppl):326

32.

McWilliams W, Trombetta M, Werts ED et al (2011) Audiometric outcomes for acoustic neuroma patients after single versus multiple fraction stereotactic irradiation. Otol Neurotol 32:297–300PubMedCrossRef

33.

Meijer OW, Vandertop WP, Baayen JC et al (2003) Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. Int J Radiat Oncol Biol Phys 56:1390–1396PubMedCrossRef

34.

Morimoto M, Yoshioka Y, Kotsuma T et al (2013) Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma. Jpn J Clin Oncol 43:805–812

35.

Mulder JJ, Kaanders JH, vanOverbeeke JJ et al (2012) Radiation therapy for vestibular schwannomas. Curr Opin Otolaryngol Head Neck Surg 20:367–371PubMedCrossRef

36.

Murphy ES, Suh JH (2011) Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys 79:985–997PubMedCrossRef

37.

Nagano O, Serizawa T, Higuchi Y et al (2010) Tumor shrinkage of vestibular schwannomas after gamma knife surgery: results after more than 5 years of follow-up. J Neurosurg 113(Suppl):122–127

38.

Noren G (2011) Oral presentation at the ISRS congress. Paris

39.

Ogino H, Shibamoto Y, Murai T et al (2011) Five-fraction cyberKnife stereotactic radiotherapy for acoustic neuroma: evaluation of three different dose levels. Int J Radiat Oncol Biol Phys 81(Suppl):286

40.

Polovnikov ES, Anikeeva OY, Filatov PV et al (2013) Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for management of vestibular schwannomas: initial experience with 17 cases. Acta Neurochir Suppl 116:37–44PubMed

41.

Qiu H, Redmond KJ, Batra S et al (2010) Hearing loss and tumor control following fractionated stereotactic radiation therapy (FSRT) for vestibular schwannoma (VS): The Johns Hopkins Hospital (JHH) experience. Int J Radiat Oncol Biol Phys 78(Suppl):9

42.

Rasmussen R, Claesson M, Stangerup SE et al (2012) Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. Int J Radiat Oncol Biol Phys 83:e607–e611PubMedCrossRef

43.

Raut VV, Walsh RM, Bath AP et al (2004) Conservative management of vestibular schwannomas—second review of a prospective longitudinal study. Clin Otolaryngol Allied Sci 29:505–514PubMedCrossRef

44.

Roos DE, Potter AE, Brophy BP (2012) Stereotactic radiosurgery for acoustic neuromas: what happens long term? Int J Radiat Oncol Biol Phys 82:1352–1355PubMedCrossRef

45.

Roosli C, Linthicum FH, Cureoglu S et al (2012) Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otol Neurotol 33:473–480PubMedCentralPubMedCrossRef

46.

Sakanaka K, Mizowaki T, Arakawa Y et al (2011) Hypofractionated stereotactic radiotherapy for acoustic neuromas: safety and effectiveness over 8 years of experience. Int J Clin Oncol 16:27–32PubMed

47.

Sawamura Y, Shirato H, Sakamoto T et al (2003) Management of vestibular schwannoma by fractionated stereotactic radiotherapy and associated cerebrospinal fluid malabsorption. J Neurosurg 99:685–692PubMedCrossRef

48.

Stangerup SE, Caye-Thomasen P, Tos M et al (2008) Change in hearing during ‘wait and scan’ management of patients with vestibular schwannoma. J Laryngol Otol 122:673–681PubMedCrossRef

49.

Stangerup SE, Caye-Thomasen P, Tos M et al (2006) The natural history of vestibular schwannoma. Otol Neurotol 27:547–552PubMedCrossRef

50.

Sughrue ME, Kane AJ, Kaur R et al (2011) A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg 114:381–385PubMedCrossRef

51.

Thomas C, Di Maio S, Ma R et al (2007) Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose. J Neurosurg 107:917–926PubMedCrossRef

52.

Van de Langenberg R, de Bondt BJ, Nelemans PJ et al (2011) Predictors of volumetric growth and auditory deterioration in vestibular schwannomas followed in a wait and scan policy. Otol Neurotol 32:338–344PubMedCrossRef

53.

Williams JA (2003) Fractionated stereotactic radiotherapy for acoustic neuromas: preservation of function versus size. J Clin Neurosci 10:48–52PubMedCrossRef

54.

Zhou W, Pool V, DeStefano F et al (2004) A potential signal of Bell’s palsy after parenteral inactivated influenza vaccines: reports to the vaccine adverse event reporting system (VAERS)—United States, 1991–2001. Pharmacoepidemiol Drug Saf 13:505–510PubMedCrossRef

Titel: Hypofractionated stereotactic radiotherapy of acoustic neuroma
Volume changes and hearing results after 89-month median follow-up
verfasst von: Manfred Kranzinger, MD
Franz Zehentmayr
Gerd Fastner
Gerhard Oberascher
Florian Merz
Olaf Nairz
Hassan Rahim
Felix Sedlmayer
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 9/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0630-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Hypofractionated stereotactic radiotherapy of acoustic neuroma

Volume changes and hearing results after 89-month median follow-up

Abstract

Purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Randomisierte MRC-RT01-Studie zu 64 Gy vs. 74 Gy beim lokalisierten primären Prostatakarzinom

Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis

Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab

Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas

Vergleich unterschiedlicher, radiochemotherapiebasierter Primärbehandlungen von nichtresektablen Glioblastomen

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie